Runner Up: Incidence of Cutaneous Adverse Events With PI3K-Akt-MTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis. J of Skin 2022, 6 (3), s39. https://doi.org/10.25251/skin.6.supp.39.